Metabolomic biomarkers in cervicovaginal fluid for detecting endometrial cancer through nuclear magnetic resonance spectroscopy

Cheng, Shih-Chun; Chen, Kueian; Chiu, Chih‐Yung; Lu, Kuan-Ying; Lu, Hsin-Chun; Chiang, Meng-Han; Tsai, Cheng‐Kun; Lo, Chi-Jen; Cheng, Mei‐Ling; Chang, Ting‐Chang; Lin, Gigin

doi:10.1007/s11306-019-1609-z

Cited by 32 publications

(36 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acylcholines enhance penetration of estradiol in tissues. Also found in tissues and CVF fluids [79]. Hexadecadienyl carnitine/ phosphatidylcholine with diacyl residue C38:1 [98] Carnitine/choline Prognosis (LVSI) Carnitine-phosphatidylcholine ratio shown to be associated with presence/absence of LVSI.…”

Section: Blood-based Predictive and Prognostic Metabolomic Ec Biomarkersmentioning

confidence: 99%

“…Inhibits proliferation without affecting apoptosis or autophagy. Also found in CVF fluids [79] Phosphatidylcholine with diacyl C42:0/phosphatidylcholine with acyl-alkyl C44:5 [98] Lipid-like (Choline derivatives) Diagnosis/early detection Specific choline derivative ratios shown to predict EC.…”

Section: Diagnosis Prognosismentioning

confidence: 99%

“…Given the anatomical continuity of the uterus and lower genital tract, there is growing interest in the potential of developing EC biomarkers based on minimally invasive sampling methodologies [45]. Cervicovaginal fluids (CVF), for example, contain cervical and endometrial gland secretions and are viable sources of EC-derived metabolites [79]. There are multiple reports on the utility of CVF for the detection of inflammatory and malignant conditions of the lower genital tract, including cervical cancer and bacterial vaginosis [45,123,124].…”

Section: Ec Detection In Minimally Invasive Genital Samplesmentioning

confidence: 99%

“…There are multiple reports on the utility of CVF for the detection of inflammatory and malignant conditions of the lower genital tract, including cervical cancer and bacterial vaginosis [45,123,124]. Cheng and colleagues used nuclear magnetic resonance spectroscopy to compare the CVF metabolomic profile of 21 EC cases and 33 non-EC controls and reported choline, formate, fumarate, phosphocholine and malate to be overexpressed in EC [79]. In contrast, phenylalanine, aspartate, asparagine, isoleucine and pyruvate were significantly downregulated.…”

Section: Ec Detection In Minimally Invasive Genital Samplesmentioning

confidence: 99%

“…In contrast, phenylalanine, aspartate, asparagine, isoleucine and pyruvate were significantly downregulated. Of these biomarker candidates, phosphocholine had the best diagnostic performance, with an AUC of 0.82 (95% CI 0.69-0.93), while the model based on phosphocholine, malate and asparagine had potential to not only predict EC but also other gynaecological malignancies [79]. Phosphocholine, a surrogate for cell proliferation, has been linked to high-grade EC [125].…”

Section: Ec Detection In Minimally Invasive Genital Samplesmentioning

confidence: 99%

See 4 more Smart Citations

Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer

et al. 2020

View full text Add to dashboard Cite

Metabolic reprogramming is increasingly recognised as one of the defining hallmarks of tumorigenesis. There is compelling evidence to suggest that endometrial cancer develops and progresses in the context of profound metabolic dysfunction. Whilst the incidence of endometrial cancer continues to rise in parallel with the global epidemic of obesity, there are, as yet, no validated biomarkers that can aid risk prediction, early detection, prognostic evaluation or surveillance. Advances in high-throughput technologies have, in recent times, shown promise for biomarker discovery based on genomic, transcriptomic, proteomic and metabolomic platforms. Metabolomics, the large-scale study of metabolites, deals with the downstream products of the other omics technologies and thus best reflects the human phenotype. This review aims to provide a summary and critical synthesis of the existing literature with the ultimate goal of identifying the most promising metabolite biomarkers that can augment current endometrial cancer diagnostic, prognostic and recurrence surveillance strategies. Identified metabolites and their biochemical pathways are discussed in the context of what we know about endometrial carcinogenesis and their potential clinical utility is evaluated. Finally, we underscore the challenges inherent in metabolomic biomarker discovery and validation and provide fresh perspectives and directions for future endometrial cancer biomarker research.

show abstract

Section: Blood-based Predictive and Prognostic Metabolomic Ec Biomarkersmentioning

confidence: 99%

Section: Diagnosis Prognosismentioning

confidence: 99%